AI주식인사이트AI Stock Insight
B

메타바이오메드

059210KOSDAQ

63.5 / 100

Reference Date: 2026-10-23

Financial Score32.0 / 40
News Sentiment12.5 / 25
Momentum9.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Roughly flat over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

MetaBioMed is a company specializing in the production and sale of medical devices and materials, including dental supplies, absorbable synthetic sutures, and cosmetic materials. The company focuses on dental nerve treatment materials and synthetic sutures, with growing demand for synthetic sutures replacing traditional animal-based products and sustained growth in the dental materials market.

Number of Employees

345people

Average Salary

52.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
8.48Industry Average 15.006.5Point

Lower than industry avg (good)

PBR
0.81Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
9.75Industry Average 8.004.0Point

In line with industry avg

Debt Ratio
1.68Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20258.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲11.3% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲42.3% (2-year basis)

ROE Trend
2.5 / 4

Avg ROE 16.9% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (8%, downtrend)

Current 3,715Won52-week high 6,22052-week low 3,490
1-month return3.0Point

1m -0.93% (flat)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-02